IL-GE-TRANSPORTATION
19.9.2018 08:02:11 CEST | Business Wire | Press release
GE Transportation (NYSE:GE) announced today at InnoTrans 2018 that Indian Railways has confirmed its acceptance of GE’s 4,500-horsepower diesel-electric Evolution Series prototype locomotive. This critical milestone was achieved following the successful completion of rigorous testing on Indian Railways’ tracks following the locomotive handover in February 2018.
“The acceptance of these locomotives is a testament to GE’s engineering depth and understanding of the customer requirements,” said Nalin Jain, President and CEO-APAC, GE Transportation. “This is a major step towards fulfilling our contract with Indian Railways. Together we will help modernize Indian Railways' fleet, significantly upgrade India's rail infrastructure and provide critical support for India's growing economy.”
A standard practice, the acceptance of the 4500hp locomotives came after months of reviewing key design aspects, documentation and a thorough validation around various parameters in the U.S. and India. The locomotives also completed additional reviews, including oscillation trials and rating and performance tests.
The new units feature an Evolution Series engine and an electronic fuel-injection system for improved fuel efficiency, as well as compliance with international emission standard UIC1. The individual axle-control AC propulsion technology will improve hauling capability and decrease life-cycle cost. The locomotives also are digitally enabled for predictive analytics to increase reliability and availability.
The locomotives are part of a $2.5 billion agreement signed in 2015 in support of the Government of India’s Public Private Partnership ‘Make in India’ program. The deal included an order for 1,000 locomotives, as well as the establishment of a new GE Transportation factory and maintenance sheds in India.
The project is on track and has achieved several key milestones. Currently, there are 45 locomotives in India that are ready for inspection and acceptance by Indian Railways. GE’s state-of-the-art Roza Maintenance Shed in the state of Uttar Pradesh, India, is ready for operations and the construction of the factory in Marhowra, Bihar, is in advanced stages towards completion. Operations will begin in the fourth quarter. Once fully operational, all locomotives built in Marhowra under the agreement will have 70 percent localized content.
Both Marhowra and Roza will set new standards in Indian Railways for manufacturing, maintenance and monitoring of diesel locomotives, as well as spark job creation and skills development across the region.
"We are aligned with the Government of India’s vision to modernize and ‘Make in India’,” said Jain. “Together, we are making tremendous progress on the vision and continuing to invest in the region.”
Visit the GE Transportation InnoTrans 2018 webpage to learn more about this week’s announcements, demos and displays. The GE Transportation booth is located at Hall 3.2, Stand 401.
About GE Transportation
At GE Transportation , we move the world and improve the world. We are a global technology leader and supplier of equipment, services and digital solutions to the rail, mining, marine, stationary power and drilling industries. Our innovations help customers deliver goods and services with greater speed and savings using our advanced manufacturing techniques and connected machines. GE Transportation is headquartered in Chicago and employs approximately 9,000 employees worldwide.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180918006157/en/
Contact:
Deia Campanelli GE Transportation (773) 297-0482 deia.campanelli@ge.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
